ReviewWorld journal of gastroenterology2008
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.The Cochrane database of systematic reviews · 2020Pooled it
- External beam radiotherapy for unresectable hepatocellular carcinoma.The Cochrane database of systematic reviews · 2017Pooled it
- Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.Digestive diseases and sciences · 2013Pooled it
- Trial
- Article
- A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.Oncology research · 2024Review
- Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Article
- LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer.Nature cancer · 2021Article
- Enrichment and identification of differentially expressed genes in hepatocellular carcinoma stem-like cells.Oncology letters · 2020Article
- Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.Oncotarget · 2017Article
- Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.Oncotarget · 2017Article
- Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.Drug delivery and translational research · 2017Article
- Preventive and Therapeutic Effects of Chinese Herbal Compounds against Hepatocellular Carcinoma.Molecules (Basel, Switzerland) · 2016Review
- Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells.Journal of translational medicine · 2015Article
- Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells.Oncology letters · 2015Article
- Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: From bench to bedside.World journal of hepatology · 2015Review
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.Nature medicine · 2014Article
- Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma.Molecular cancer · 2014Article
- Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.